CN1027179C - 利用啤酒酵母基因bari分泌异种蛋白的方法 - Google Patents

利用啤酒酵母基因bari分泌异种蛋白的方法 Download PDF

Info

Publication number
CN1027179C
CN1027179C CN86107554A CN86107554A CN1027179C CN 1027179 C CN1027179 C CN 1027179C CN 86107554 A CN86107554 A CN 86107554A CN 86107554 A CN86107554 A CN 86107554A CN 1027179 C CN1027179 C CN 1027179C
Authority
CN
China
Prior art keywords
bar1
gene
plasmid
fragment
promotor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN86107554A
Other languages
English (en)
Chinese (zh)
Other versions
CN86107554A (zh
Inventor
维维安·L·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN86107554A publication Critical patent/CN86107554A/zh
Application granted granted Critical
Publication of CN1027179C publication Critical patent/CN1027179C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN86107554A 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法 Expired - Lifetime CN1027179C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791,305 1985-10-25
USPCT/US86/02198 1986-10-20
PCT/US1986/002198 WO1987002670A1 (fr) 1985-10-25 1986-10-20 Procede d'utilisation de bar1 pour la secretion de proteines etrangeres

Publications (2)

Publication Number Publication Date
CN86107554A CN86107554A (zh) 1987-08-26
CN1027179C true CN1027179C (zh) 1994-12-28

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86107554A Expired - Lifetime CN1027179C (zh) 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法

Country Status (13)

Country Link
EP (1) EP0243465A1 (fr)
JP (1) JP2523562B2 (fr)
CN (1) CN1027179C (fr)
AU (2) AU6543286A (fr)
CA (1) CA1316133C (fr)
CZ (1) CZ284251B6 (fr)
DK (1) DK320287A (fr)
FI (1) FI872801A (fr)
HU (1) HU206897B (fr)
IE (1) IE63822B1 (fr)
SK (1) SK279041B6 (fr)
UA (1) UA41863C2 (fr)
WO (1) WO1987002670A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
AU2334088A (en) * 1987-10-02 1989-05-18 Zymogenetics Inc. Bar1 secretion signal
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
EP0387319B1 (fr) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Sequences conductrices secretoires
JPH05505308A (ja) * 1990-03-13 1993-08-12 ハワイ・バイオテクノロジー・グループ・インコーポレイテツド アオパンカビ発現システム
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
CN102080070B (zh) 1995-03-17 2016-01-20 诺沃奇梅兹有限公司 新的内切葡聚糖酶
DK1975177T3 (da) 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
CA2395713C (fr) 2000-01-10 2012-04-10 Torben Lauesgaard Nissen Produits conjugues g-csf
WO2001058935A2 (fr) 2000-02-11 2001-08-16 Maxygen Aps MOLECULES DE TYPE FACTEUR VII OU VIIa
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
BR0208203A (pt) 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2003027147A2 (fr) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation humain
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
JP2008538290A (ja) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
WO2007020256A1 (fr) 2005-08-16 2007-02-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII
WO2007103447A2 (fr) 2006-03-06 2007-09-13 Humagene, Inc. Procede de preparation de la thrombine recombinante humaine et du fibrinogene
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
WO2008137471A2 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interféron bêta modifiés et leurs utilisations
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
KR101870378B1 (ko) 2009-07-17 2018-06-25 릭스하스피탈렛 보체 활성화의 억제제로서의 ｍａｓｐ 이소형
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP3815708A1 (fr) 2010-03-05 2021-05-05 Omeros Corporation Molécules chimères inhibitrices de l'activation du complément
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
EP2649178B8 (fr) 2010-12-09 2017-08-30 Institut Pasteur Méthode basée sur mgmt pour obtenir un haut rendement dans l'expression des protéines recombinantes
MX349562B (es) 2011-12-09 2017-08-02 Pasteur Institut Ensayo de inmuno deteccion multiplex.
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
BR112014018630A2 (pt) 2012-02-09 2017-07-04 Var2 Pharmaceuticals Aps alvejamento de glicanos de sulfato de condroitina
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
MX2020011529A (es) 2018-05-01 2021-01-29 Ambrx Inc Un metodo para optimizar la expresion de anticuerpos.
EP3821244A1 (fr) 2018-07-13 2021-05-19 Varct Diagnostics ApS Isolement de cellules circulantes d'origine foetale à l'aide d'une protéine de malaria recombinante var2csa
DK3849614T3 (da) 2018-09-11 2024-02-26 Ambrx Inc Interleukin-2-polypeptidkonjugater og anvendelser deraf
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
EP4136459A1 (fr) 2020-04-13 2023-02-22 Abbott Laboratories Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022147147A1 (fr) 2020-12-30 2022-07-07 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN115806889B (zh) * 2022-09-28 2024-06-11 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法

Also Published As

Publication number Publication date
DK320287D0 (da) 1987-06-23
JP2523562B2 (ja) 1996-08-14
SK776486A3 (en) 1998-06-03
UA41863C2 (uk) 2001-10-15
SK279041B6 (sk) 1998-06-03
CA1316133C (fr) 1993-04-13
FI872801A0 (fi) 1987-06-24
EP0243465A1 (fr) 1987-11-04
HUT43624A (en) 1987-11-30
AU676132B2 (en) 1997-03-06
CZ284251B6 (cs) 1998-10-14
IE63822B1 (en) 1995-06-14
AU6543286A (en) 1987-05-19
CN86107554A (zh) 1987-08-26
JPS63501614A (ja) 1988-06-23
IE862804L (en) 1987-04-25
DK320287A (da) 1987-06-23
WO1987002670A1 (fr) 1987-05-07
HU206897B (en) 1993-01-28
AU7400391A (en) 1991-07-18
FI872801A (fi) 1987-06-24
CZ776486A3 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
CN1027179C (zh) 利用啤酒酵母基因bari分泌异种蛋白的方法
CA1340772C (fr) Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
CN1069346C (zh) 用解脂亚罗威阿酵母转化株表达和分泌异源蛋白质
EP0123544A2 (fr) Procédé d'expression de protéines hétérologues dans les levures, vecteurs d'expression et micro-organismes du genre levure à cet effet
EP0123289A2 (fr) Facteur-A et ses signaux de traitement
CN1032367A (zh) 含有指导异源多肽分泌的克鲁维酵母α-因子前导顺序的DAN组建物
EP3874047B1 (fr) Production de protéines régulées à source de carbone dans une cellule hôte recombinante
US9012367B2 (en) Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
EP0220689B1 (fr) Méthode permettant l'utilisation de BAR1 pour la sécrétion de protéines étrangères
CN112105737B (zh) 生产目标蛋白质的宿主细胞
KR100798894B1 (ko) 재조합단백질 생산용 단백질융합인자
CN1302333A (zh) 在酵母中制备目的多肽的方法
JP3732516B2 (ja) タンパク質の製造法
WO2024133538A1 (fr) Cellules hôtes à inactivation de pat1 permettant une productivité accrue de protéine spécifique
KR100626753B1 (ko) 재조합 단백질 생산용 맞춤형 단백질융합인자의 초고속선별 방법
EP0188555A1 (fr) Vehicule de clonage de levure
CN1309712A (zh) 在转化的酵母细胞中生产蛋白质的方法
CN1035127A (zh) 小蛭素衍生物
KR20050076139A (ko) 단백질 분비 생산을 유도하는 단백질융합인자

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term